The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces increasing concerns about monopolies. A few dominant firms control a significant portion of the market, potentially hampering competition and driving up prices for consumers. This situation raises worries about the long-term impact on patient access to aff